Bleeding diathesis: Difference between revisions
Jump to navigation
Jump to search
Line 15: | Line 15: | ||
! | ! | ||
! | ! | ||
!History | |||
! colspan="5" |Clinical manifestation | |||
! colspan="5" |Laboratory testing | |||
|- | |||
! | |||
! | |||
! | |||
! | |||
! | |||
!'''Petechiae''' | |||
!'''Ecchymoses''' | |||
!'''Menorrhagia''' | |||
!Hematomas | |||
!Hemarthrosis | |||
!platelet count | |||
!Bleeding time (BT) | |||
!Prothrombin time (PT) | |||
!Platelet count activated partial thromboplastin time (aPTT) | |||
!Thrombin time (TT) | |||
|- | |- | ||
| rowspan="15" |Platelet disorders | | rowspan="15" |Platelet disorders | ||
| rowspan="7" |Thrombocytopenia | | rowspan="7" |Thrombocytopenia | ||
|Infection-Induced Thrombocytopenia<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span> | |Infection-Induced Thrombocytopenia<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
|Drug-Induced Thrombocytopenia<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span> | |Drug-Induced Thrombocytopenia<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
|Heparin-Induced Thrombocytopenia<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span> | |Heparin-Induced Thrombocytopenia<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
|Immune Thrombocytopenic Purpura (ITP)<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span> | |Immune Thrombocytopenic Purpura (ITP)<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
|Inherited Thrombocytopenia<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span> | |Inherited Thrombocytopenia<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
|Thrombotic Thrombocytopenic Purpura (TTP)<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span> | |Thrombotic Thrombocytopenic Purpura (TTP)<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
|Hemolytic Uremic Syndrome<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span> | |Hemolytic Uremic Syndrome<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
|Thromobcytosis<span name="harr_c115s002s003p001"></span><span name="9100800"></span> | |Thromobcytosis<span name="harr_c115s002s003p001"></span><span name="9100800"></span> | ||
|Thrombocytosis in response to acute or chronic inflammation has not been associated with an increased thrombotic risk. In fact, patients with markedly elevated platelet counts (>1.5 million), usually seen in the setting of a myeloproliferative disorder, have an increased risk of bleeding. This appears to be due, at least in part, to acquired von Willebrand disease (VWD) due to platelet-VWF adhesion and removal. | |Thrombocytosis in response to acute or chronic inflammation has not been associated with an increased thrombotic risk. In fact, patients with markedly elevated platelet counts (>1.5 million), usually seen in the setting of a myeloproliferative disorder, have an increased risk of bleeding. This appears to be due, at least in part, to acquired von Willebrand disease (VWD) due to platelet-VWF adhesion and removal. | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
| rowspan="7" |Qualitative Disorders of Platelet Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | | rowspan="7" |Qualitative Disorders of Platelet Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | ||
|Inherited Disorders of Platelet Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | |Inherited Disorders of Platelet Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
|Acquired Disorders of Platelet Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | |Acquired Disorders of Platelet Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
| rowspan="5" |von Willebrand Disease<span name="harr_c115s002s005p001"></span><span name="9100810"></span> | | rowspan="5" |von Willebrand Disease<span name="harr_c115s002s005p001"></span><span name="9100810"></span> | ||
|Type 1 | |Type 1 | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
|Type 2 A | |Type 2 A | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
|Type 2 B | |Type 2 B | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
|Type 2 M | |Type 2 M | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
|Type 3 | |Type 3 | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| rowspan="2" |Vessel wall disorders | | rowspan="2" |Vessel wall disorders | ||
|Metabolic and Inflammatory Disorders | |Metabolic and Inflammatory Disorders | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
|Inherited Disorders of the Vessel Wall | |Inherited Disorders of the Vessel Wall | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 72: | Line 278: | ||
| rowspan="12" |Coagulation disorders | | rowspan="12" |Coagulation disorders | ||
|Fibrinogen deficiency | |Fibrinogen deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
|Prothrombin deficiency | |Prothrombin deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Factor V deficiency | | rowspan="1" |Factor V deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Factor VII deficiency | | rowspan="1" |Factor VII deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Factor VIII deficiency | | rowspan="1" |Factor VIII deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Factor IX deficiency | | rowspan="1" |Factor IX deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Factor X deficiency | | rowspan="1" |Factor X deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Factor XI deficiency | | rowspan="1" |Factor XI deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Factor XII deficiency | | rowspan="1" |Factor XII deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
|HK deficiency | |HK deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Prekallikrein deficiency | | rowspan="1" |Prekallikrein deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Factor XIII deficiency | | rowspan="1" |Factor XIII deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 121: | Line 459: | ||
| rowspan="3" |[[Hemophilia]] | | rowspan="3" |[[Hemophilia]] | ||
|Type A deficiency | |Type A deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
|Type B deficiency | |Type B deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
|Type C deficiency | |Type C deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 134: | Line 505: | ||
| rowspan="4" |Rare diseases | | rowspan="4" |Rare diseases | ||
|Disseminated Intravascular Coagulation | |Disseminated Intravascular Coagulation | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
|Vitamin K Deficiency | |Vitamin K Deficiency | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
|Coagulation Disorders Associated with Liver Failure | |Coagulation Disorders Associated with Liver Failure | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
|Acquired Inhibitors of Coagulation Factors | |Acquired Inhibitors of Coagulation Factors | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
|} | |} |
Revision as of 16:21, 8 August 2018
Bleeding diathesis main page |
|
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Mehrian Jafarizade, M.D [2]
Overview
Classification
Differential Diagnosis
History | Clinical manifestation | Laboratory testing | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Petechiae | Ecchymoses | Menorrhagia | Hematomas | Hemarthrosis | platelet count | Bleeding time (BT) | Prothrombin time (PT) | Platelet count activated partial thromboplastin time (aPTT) | Thrombin time (TT) | |||||
Platelet disorders | Thrombocytopenia | Infection-Induced Thrombocytopenia | ||||||||||||
Drug-Induced Thrombocytopenia | ||||||||||||||
Heparin-Induced Thrombocytopenia | ||||||||||||||
Immune Thrombocytopenic Purpura (ITP) | ||||||||||||||
Inherited Thrombocytopenia | ||||||||||||||
Thrombotic Thrombocytopenic Purpura (TTP) | ||||||||||||||
Hemolytic Uremic Syndrome | ||||||||||||||
Thromobcytosis | Thrombocytosis in response to acute or chronic inflammation has not been associated with an increased thrombotic risk. In fact, patients with markedly elevated platelet counts (>1.5 million), usually seen in the setting of a myeloproliferative disorder, have an increased risk of bleeding. This appears to be due, at least in part, to acquired von Willebrand disease (VWD) due to platelet-VWF adhesion and removal. | |||||||||||||
Qualitative Disorders of Platelet Function | Inherited Disorders of Platelet Function | |||||||||||||
Acquired Disorders of Platelet Function | ||||||||||||||
von Willebrand Disease | Type 1 | |||||||||||||
Type 2 A | ||||||||||||||
Type 2 B | ||||||||||||||
Type 2 M | ||||||||||||||
Type 3 | ||||||||||||||
Vessel wall disorders | Metabolic and Inflammatory Disorders | |||||||||||||
Inherited Disorders of the Vessel Wall | ||||||||||||||
Coagulation disorders | Fibrinogen deficiency | |||||||||||||
Prothrombin deficiency | ||||||||||||||
Factor V deficiency | ||||||||||||||
Factor VII deficiency | ||||||||||||||
Factor VIII deficiency | ||||||||||||||
Factor IX deficiency | ||||||||||||||
Factor X deficiency | ||||||||||||||
Factor XI deficiency | ||||||||||||||
Factor XII deficiency | ||||||||||||||
HK deficiency | ||||||||||||||
Prekallikrein deficiency | ||||||||||||||
Factor XIII deficiency | ||||||||||||||
Hemophilia | Type A deficiency | |||||||||||||
Type B deficiency | ||||||||||||||
Type C deficiency | ||||||||||||||
Rare diseases | Disseminated Intravascular Coagulation | |||||||||||||
Vitamin K Deficiency | ||||||||||||||
Coagulation Disorders Associated with Liver Failure | ||||||||||||||
Acquired Inhibitors of Coagulation Factors |